4.8100 0.00 (0.00%)
After hours: 4:00PM EDT
|Bid||4.7900 x 1200|
|Ask||4.8000 x 1000|
|Day's Range||4.6400 - 4.8600|
|52 Week Range||0.9800 - 9.6800|
|Beta (5Y Monthly)||2.37|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 05, 2020 - Aug 12, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.00|
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]
Moody's Investors Service, ("Moody's") today assigned a B3 rating to Carrols Restaurant Group, Inc.'s ("Carrols") proposed $50 million term loan add-on. The net proceeds will be used to repay outstanding loans under the company's revolving credit facility, thereby improving liquidity. Carrols' B3 corporate family rating, B3-PD probability of default rating, B3 first lien bank loan and SGL-3 speculative grade liquidity ratings remain unchanged.
Carrols Restaurant Group, Inc. ("Carrols" or the "Company") (Nasdaq: TAST) today announced that due to the public health impact of the coronavirus outbreak (COVID-19) and to support the health and well-being of the Company’s management, stockholders and other meeting participants, the Company's 2020 Annual Meeting of Stockholders will be changed from a hybrid meeting (in person and virtual meeting) to a virtual only meeting to be held solely by means of remote communication. Stockholders will not be able to attend the 2020 Annual Meeting of Stockholders in person.
With that, I will now turn the call over to our chairman and CEO, Dan Accordino. As you will recall from our Q4 call, we began 2020 with optimism with respect to what we intended to accomplish this year in improving operations across our restaurants, resetting our priorities in terms of capital allocation, and generating free cash flow.
Carrols Restaurant (TAST) delivered earnings and revenue surprises of 0.00% and -3.14%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Carrols Restaurant Group (NASDAQ:TAST) rose 2.3% in pre-market trading after the company reported Q1 results.Quarterly Results Earnings per share decreased 31.03% year over year to ($0.38), which missed the estimate of ($0.35).Revenue of $351,518,000 rose by 20.88% year over year, which missed the estimate of $366,860,000.Outlook Carrols Restaurant Group hasn't issued any earnings guidance for the time being.Revenue guidance hasn't been issued by the company for now.How To Listen To The Conference Call Date: May 07, 2020View more earnings on TASTTime: 08:02 AM ETWebcast URL: https://edge.media-server.com/mmc/p/tutvg7wnPrice Action Company's 52-week high was at $10.6552-week low: $0.98Price action over last quarter: down 28.57%Company Overview Carrols Restaurant Group Inc is a United States based restaurant company. It owns and operates Burger King restaurants in the Northeastern, Midwestern, and Southeastern United States. The Burger King restaurants are quick-service restaurants featuring hamburgers and other sandwiches.See more from Benzinga * Triple-S Management: Q1 Earnings Insights * Sprague Resources: Q1 Earnings Insights * Oaktree Strategic Income: Q2 Earnings Insights(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Carrols Restaurant Group, Inc. ("Carrols" or the "Company") (Nasdaq: TAST) today reported financial results for the first quarter ended March 29, 2020 and provided a business update.
Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Carrols Restaurant Group, Inc. New York, May 04, 2020 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Carrols Restaurant Group, Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.
Carrols Restaurant Group, Inc. ("Carrols") (Nasdaq: TAST), the largest BURGER KING® franchisee in the United States, today announced that Daniel T. Accordino, Chairman and Chief Executive Officer, and Anthony E. Hull, Chief Financial Officer, will host a conference call to discuss first quarter 2020 financial results and provide a business update on Thursday, May 7, 2020 at 8:30 AM ET. A press release with first quarter 2020 financial results will be issued at 7:00 AM ET that same day.
Carrol's is supported by its good relationship with Restaurant Brands International, Inc. ("RBI") (owner of Burger King), its position as the largest franchisee in the Burger King system (14% of units) and RBI's 15% equity ownership of Carrols. Carrols' is constrained by the need to digest acquisitions and ramp-up new builds that have been added to the system at a rapid pace over the past few years, the competitive and promotional operating environment, and wage and cost inflation.
There's been a major selloff in Carrols Restaurant Group, Inc. (NASDAQ:TAST) shares in the week since it released its...
Pomerantz LLP is investigating claims on behalf of investors of Carrols Restaurant Group, Inc. (“Carrols” or the “Company”) (NASDAQ: TAST) Such investors are advised to contact Robert S. Willoughby at firstname.lastname@example.org or 888-476-6529, ext. The investigation concerns whether Carrols and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. On February 25, 2020, Carrols issued a press release reporting its financial results for the fourth quarter and full year ended December 29, 2019.
NEW YORK, ACCESSWIRE / February 28, 2020 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Carrols Restaurant Group, Inc. ("Carrols" or the "Company") ...
There's been a major selloff in Carrols Restaurant Group, Inc. (NASDAQ:TAST) shares in the week since it released its...
NEW YORK, NY / ACCESSWIRE / February 25, 2020 / Carrols Restaurant Group, Inc. (NASDAQ:TAST) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on February ...
Investors want to see a return on investment, it's as simple as that. Regardless of the size of the investment, the end goal remains the same. Sure, there are several ways to go about achieving this objective, yet time after time Wall Street observers circle back to a single tried and true strategy.Growth investing involves identifying the stocks with long-term growth prospects that go above and beyond those of their peers.It should be noted, though, that plays in the growth-stock arena can sometimes come with a price tag to match their huge potential for gains. However, there are compelling names out there that don't cost a fortune.InvestorPlace - Stock Market News, Stock Advice & Trading TipsWhile some naysayers might argue that you get what you pay for, others will point out that stocks trading at low levels can represent some of the most compelling names on the Street, with entry points that make them even more attractive. * 7 Stocks to Buy for February Contrarians With this in mind, I used TipRanks' Stock Screener tool during my own search for affordable growth names. After sorting the results by current share price, analyst consensus and price target, the tool revealed three stocks that have received a wealth of support from Wall Street analysts, all under $5 per share. To top it all off, each boasts massive upside potential from current levels. Matinas BioPharma (MTNB)Source: Shutterstock Like the name suggests, Matinas BioPharma Holdings (NYSE MKT:MTNB) is a biopharma focused on the development of lead candidate, MAT9001, its prescription-only omega-3 fatty acid drug for cardiovascular and metabolic conditions. After the FDA approved the label expansion of Amarin's Vascepa drug to include cardiovascular disease patients with high triglycerides of greater than 150 mg/dL, some analysts believe that MTNB's $1.44 share price is a bargain.Piper Sandler analyst Edward Tenthoff tells investors that his bullish thesis is primarily driven by earlier data published by MTNB. Back in 2015, the company reported that during a Phase 1 study, MAT9001 was found to have produced a greater reduction of triglycerides, with the figure coming in at 33% compare to Vascapa's 11%.The drug is currently being evaluated in the Phase 2 ENHANCE-IT study versus Vascepa. With data slated for release in the fourth quarter of this year, big things could be on the way. Tenthoff argues MTNB could start a single Phase 3 severe hypertriglyceridemia trial in 2021 and see potential approval in 2023. In addition, he thinks that the importance of omega-3-based medicines is expanding.All of the above factors prompted the analyst to start his MTNB coverage by publishing an "overweight" rating and setting a $3 price target. Should the target be met, shares could be in for a 108% gain over the next twelve months.Similarly, the rest of the Street takes a bullish approach when it comes to MTNB. Out of four analysts tracking the name over the last three months, 100% see the stock as a "buy," making the consensus rating a "strong buy." Given the $3.25 average price target, the upside potential of 126% surpasses Tenthoff's estimate. See the MTNB stock analysis. Northern Oil And Gas (NOG)Source: Shutterstock Northern Oil and Gas (NYSE MKT:NOG) is one of the primary non-operator franchises in the Bakken and Three Forks plays in the Williston Basin of North Dakota and Montana. Its total footprint, which lands at about 165,000 acres, as well as its proved reserves of 65.3 million barrels of oil equivalent at year-end 2015, has helped cement its status as one of the leading players in the space. Its $1.69 price tag seems almost too good to be true.Back in December, the company gave investors a reason to get excited after it announced that it would start paying out a quarterly dividend. The first dividend will come in at two cents per share, payable in April 2020. In addition, the forward yield lands at 3.14%.This news prompted Imperial Capital analyst Jason Wangler to boost his rating from "in-line" to "outperform." He argues that while the dividend is modest, it demonstrates that NOG has taken steps in the right direction in terms of its balance sheet over the last two years. On top of this, it also means that the name can be thought of as a yield vehicle.It makes sense, then, that in addition to the upgrade, Wangler bumped up the price target from $2 to $2.50. At this new target, the upside potential comes in at 48%. * 7 Under-the-Radar European Stocks to Buy for 2020 When it comes to other analyst activity, it has been relatively quiet on Wall Street. That being said, the two other analysts that published a review in the last three months rated NOG as a "buy," making the Street consensus a "strong buy." Not to mention the $3.25 average price target brings the upside potential to 92%. See the NOG stock analysis. Durect Corporation (DRRX) Source: Shutterstock Durect Corporation (NASDAQ:DRRX) has a simple objective: to transform medicine. It wants to develop drugs that can provide meaningful advances in patient health and wellbeing. At the bargain price of $2.12 per share, analysts warn investors that if they wait too long, they could miss out on the opportunity.While investor concern has definitely emerged, Craig-Hallum analyst Francois Brisebois is still very much on board. Fears among investors have been driven by the company's announcement that the AdCom vote for its Posimir drug's Class 2 New Drug Application (NDA) resubmission was split right down the middle.As a result, Brisebois doesn't assign any value to the drug in the model. Rather, he highlights its DUR-928 candidate for primary alcoholic hepatitis as DRRX's primary value driver, calling early efficacy and safety data incredibly encouraging. On top of this, the analyst argues that the combination of the current poor standard of care and the $3 billion total addressable market played into his conclusion that investors should buy on any weakness.With this in mind, Brisebois kicked off his DRRX coverage by issuing a "buy" rating. In addition, he set a Street high price target of $6, implying a staggering 183% upside potential.Meanwhile, the rest of the Street also likes what it's seeing. A "strong buy" consensus rating breaks down into three "buys" and a single "hold." While less aggressive than that of Brisebois, the $4.65 average price target still puts the potential twelve month gain at 119%. See the DRRX stock analysis. Carrols Restaurant Group (TAST)Source: Shutterstock While the name Carrols Restaurant Group (NASDAQ:TAST) might not ring any bells, but you've probably heard of its restaurants Burger King and Popeyes. It is true that shares took a pretty substantial hit following its preliminary fourth quarter results. Now at just $4.80 apiece, Deutsche Bank's Brian Mullan is still in the restaurant company's corner.The negative reaction came largely as a result of Burger King's same store sales (SSS) results. At 2%, the figure falls well below the implied guidance's range of 4% to 5% range and reflects a deceleration in November and December.However, Mullan tells investors that there's a silver lining. Management noted that the focus will shift towards managing both net leverage levels and free cash flow. "While management wasn't explicit with its plans, reading the tea leaves our sense is that these comments could pertain to either: 1) a reduced pace of acquisitions for the foreseeable future, 2) a potential slowdown in new unit development, or 3) all of the above," he explained.This combined with the new CFO appointment implies that the plans for the above are "… fluid and evolving. We think the key takeaway here is that management is mindful of the market's perception of TAST's net leverage levels, and that it has several options at its disposal to address this, should it see fit," Mullan added.Taking all of this into consideration, the analyst left his "buy" rating and $8 price target as is. This means that shares could potentially surge 67% in the next twelve months. * 7 Biometrics Stocks That Will Help Shape the Next Decade Judging by the consensus breakdown, the rest of the Street is in agreement. With only "buy" ratings assigned in the last three months, the message is clear: TAST is a "strong buy." It also doesn't hurt that the $8.83 average price target suggests 84% upside potential. See the TAST stock analysis. VBI Vaccines (VBIV)Source: Shutterstock VBI Vaccines' (NASDAQ:VBIV) claim to fame is its Sci-B-Vac product, which was the first vaccine to be commercially-approved for hepatitis B. The vaccine is currently available in Israel and ten other countries. It recently completed its Phase 3 program in the U.S., Europe and Canada. After new data was released earlier this month, analysts have been impressed, to say the least.On Jan. 9, the company, which goes for $1.46 a share, announced that Sci-B-Vac had met both its primary and secondary endpoints in the second Pivotal Phase 3 CONSTANT study. Both management and investors were excited by the results as they demonstrate that the candidate is both safe and highly-potent.While this outcome is encouraging, VBIV's potential extends beyond Sci-B-Vac. BMO Capital analyst Do Kim highlights its VBI-1901 and VBI-2601 candidates as potentially driving significant upside. According to the analyst, updated Phase 1/2a tumor response and survival data for VBI-1901's use in glioblastoma multiforme (GMB) is slated for release some time in the first half of 2020. Should the results be favorable, VBIV could develop a modified version to target other EBV+ cancers. On top of this, VBI-2601 proof-of-concept for use in chronic hepatitis B infection (HBV) is expected in the second half of the year."We believe the initial data could be meaningful for VBI's vaccine approach for a functional HBV cure, with the potential for combining beyond antivirals, including Brii's VIR-2218 and other HBsA RNAi. With an estimated 257 million chronically infected patients worldwide, we believe HBV represents a significant market opportunity for a functional cure," Kim commented.Based on everything the healthcare name has going for it, Kim reiterated his "outperform" rating and $5 price target, indicating 242% upside potential.Out of three total analysts that have thrown their hat in with a review, 100% sided with the bulls, making the consensus rating a "strong buy." See the VBIV stock analysis.TipRanks offers investors the latest insight into eight different sectors by tracking the activity of over 5,000 Wall Street analysts. As of this writing, Maya Sasson did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Stocks to Buy for February Contrarians * 10 of the Top Franchise Stocks to Buy Now * 5 High-Yield Stocks With High Free Cash Flow Yields The post 5 Stocks Under $5 With Colossal Growth Prospects appeared first on InvestorPlace.
Whatever the reason a stock is trading for under $5 a share, these stocks are conversation starters. Some will point out the low valuation of these companies presents opportunity for upside which will be hard to come by when investing in a large-cap. What’s more, you can load up on a much larger number of shares than you could with a stock trading in triple or even double digits.On the other hand, the naysayers argue these tickers are likely to have bad fundamentals and face too many obstacles and, therefore, are more of a speculative shot at lottery like returns than an investment.Either way, both are right, and both could be wrong, too. The trick, as with any investment, is to find the most compelling opportunities the market presents.We went on our own intrepid search for 3 stocks trading at a bargain price, specifically looking for ones which those in the know think are poised to take off over the next 12 months. We used TipRanks’ Stock Screener tool which revealed that in addition to the low valuation, all three currently have a “Strong Buy” consensus rating. Let’s dive in.Orbcomm Inc. (ORBC)Orbcomm operates in an industry that is expected to grow substantially in the new decade. Orbcomm provides machine-to-machine (M2M) solutions across the globe, with its Internet of Things (IoT) technology used to track and monitor large assets. The company’s main markets are in transportation, heavy equipment, and government services, amongst others. Orbcomm is the only commercial satellite network 100% dedicated to M2M.The stock experienced a crushing 2019, losing almost 50% over the year due to disappointing earnings reports and transportation industry headwinds; Economic data suggests that in November, more than 1,000 truck drivers lost their jobs. Further data from October indicates heavy truck order activity is down 51% from 2018 levels.Canaccord's Michael Walkley expects the soft industrial data to continue until mid-2020 and believes it will affect some of Orbcomm’s hardware sales. Nevertheless, the analyst thinks “the shares have limited downside risk at the current valuation.”The 5-star analyst expounded, “Despite our cautious view of macro trends for a portion of Orbcomm’s transportation business unit, we believe the shares have priced in soft near-term hardware sales trends. With Orbcomm’s shares trading roughly 4X our 2021 adjusted EBITDA estimate, we view the risk reward on the shares as very positive… We believe if management can execute, the shares should return to higher multiples.”What does it mean, then? It means that Walkley keeps his Buy rating on Orbcomm. To reflect the headwinds, though, the price target comes down a notch, from $10 to $9. The reduced figure still represents outstanding returns in the shape of 132% could be in store over the next twelve months. (To watch Walkley’s track record, click here)Overall, the Street is with Walkley. 2 additional Buy ratings given to the M2M solutions provider over the last three months add up to a Strong Buy consensus rating. The average price target comes in at $7.67 and implies potential upside of a hefty 98%. (See Orbcomm stock analysis on TipRanks)Plug Power (PLUG)From M2M technology, we move on to another very modern solution, hydrogen fuel cell technology, or renewable energy. Plug Power’s fuel cell systems are designed to replace conventional batteries in electric vehicles and industrial trucks.In sharp contrast to ORBC, PLUG had an outstanding 2019. Its share price added considerable muscle in the shape of 154% throughout the year. Investors were buoyed by strong forecasts, management purchasing company stock, and an ambitious five-year plan, projecting revenue of $1 billion and adjusted EBITDA of $200 million.More good news has extended the rally into 2020; Plug is up by over 23% year-to-date following the announcement that it was awarded a $172 million contract for hydrogen fuel cell deployments from a Fortune 100 customer.B.Riley FBR’s Christopher Van Horn argues PLUG’s “stock and the fuel cell technology seem to be at an inflection point.” The 4-star analyst thinks the contract demonstrates the company’s competitive position, and with an addressable market of $30 billion, believes there should be more opportunities for PLUG coming up.Van Horn said, “PLUG has an implied 35% five-year CAGR from our 2019 revenue estimate and an almost 90% four-year CAGR from our 2020 adjusted EBITDA estimate. We believe this growth could come from its existing customer base, including Wal-Mart, Amazon, and others, as well as new customers. We think this award at roughly $172 million over two years is another step in the right direction to achieve these goals.”Therefore, Van Horn reiterated his Buy call on PLUG along with a price target of $6. This indicates upside potential of 54% over the next 12 months. (To watch Van Horn’s track record, click here)Is the Street ready to plug into PLUG? Yes, it is. The 5 Buy ratings and solitary Hold given over the last three months make the consensus rating a Strong Buy. An average price target of $4.50 puts the upside potential at 15%. (See Plug Power stock analysis on TipRanks)Carrols Restaurant (TAST)From modern solutions, we move to the food industry, where we take a seat at Carrols Restaurant. The company operates the largest Burger King franchisee in the world.It often happens that a stock trading for under $5 used to have a much larger market-cap, but for whatever reason, has lost its luster, and is now much cheaper. For Carrols, last year was a combination of underwhelming earnings reports plus a bizarre software mix up which charged customers incorrectly for discount meals that cost the company $8.3 million. As a result, the stock took a beating in 2019, starting the year at $9.84 and ending it down 28% at $7.05.The company recently announced preliminary 4Q19 results which has further worried investors; In October, Carrols had anticipated 4%-plus SSS (same store sales) for Burger King in its upcoming report, but the new data indicates the SSS figure lands at only 2%. Since then, the share price has dropped further and is down by 32% since the start of the year.So, should you stay away from TAST? Not according to SunTrust Robinson’s Jake Bartlett. The 5-star analyst explained, “TAST attributed the SSS miss to decreased traffic as Burger King laps its '10 Nuggets for $1' promotion last year (through mid-Feb.), a 'Winter Whopperland' game promotion in December that drove app downloads, but not sales, a potential impact from Popeye's new chicken sandwich (TAST's Popeyes 4Q19 21.2%-plus), a potential impact from MCD's '2 for $5' promotion and weak breakfast sales (negative in 4Q19 as lapped the $0.89 pancake promotion). While disappointing, TAST appears encouraged by upcoming menu innovation at Burger King… The promotional environment should remain balanced and significant acquisitions for both Popeyes and Burger King stores are expected in '20.”Accordingly, then, Bartlett reiterated a Buy recommendation on Carrols and kept his $14 price target. The target implies upside potential of a whopping 192%. (To watch Bartlett’s track record, click here)Currently, there are few on the Street taking a bite out of Carrols, but those who are, like the (TAST)e. A Strong Buy consensus rating is formed of 3 Buys, and at $8.83, the average price target suggests potential upside of a handsome 84%. (See Carrols Restaurant stock analysis on TipRanks)
Are you buying what Wall Street is selling today? If it involves Beyond Meat (NASDAQ:BYND) stock I'd suggest politely declining headline worries and instead work on placing a first order in shares or even a second helping. Let me explain.Source: calimedia / Shutterstock.com Wednesday wasn't a great day using a straightforward price performance metric in BYND shares. The faux-meat upstart and recent IPO finished the day off by 5.25%. Thursday saw another 3.7% trimmed off the price before after-hours trading gave back 2%To be sure, a drop of that size could be and most often is considered a large eye-poke for most publicly traded companies. Importantly though, in Beyond Meat stock you could rightfully label the price action a case of mild indigestion.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe fact is BYND stock has been one of the markets standout performers in early 2020. Shares have soared more than 60% in less than three weeks. Earlier this month rival and privately held Impossible Meats announced it was axing its pursuit to get on to McDonald's (NYSE:MCD) menu. That's good news as Beyond Meat looks to lock up its own licensing agreement with the fast food behemoth. And in turn, investors sent shares soaring by as much as 80% in six trading sessions. * 9 Up-and-Coming Small-Cap Stocks to Watch This week BYND stock saw another supportive flame lit under shares. On Tuesday Beyond Meat jumped 18% after coffee and breakfast-fix giant Starbucks (NASDAQ:SBUX) announced plans to explore plant-based menu options as it strives to become a "resource-positive" company.In 2020's more complete context, the combined Wednesday-Thursday 8.3% grilling is mostly insignificant and easily chalked up to simple profit-taking. But if you're aching to point fingers somewhere else, look no further than Burger King's largest franchisee Carrols Restaurant Group (NASDAQ:TAST).On Wednesday the company announced sales of its Impossible Foods-based Whooper are off to 28 per store per day from 32 in its last reporting period. Unsurprisingly, the news stoked concern the fake meat market is dead in its tracks. But is it? At the end of the day, if baby bull markets are raised out of fear and forced to climb walls of worry, BYND stock has a lot going for it off and on the price chart. Beyond Meat Stock, by the Chart Source: Charts by TradingViewYou could say I've been an early advocate of Beyond Meat stock. Not only is the company's product routinely found in my fridge, but in early January, I also detailed an early-bird buy strategy at $81 in front of BYND's massive breakout from a key congestion pattern. * The Top 5 Dow Jones Stocks to Buy for 2020 The resulting price action has re-established Beyond Meat's deserved reputation as a volatile momentum stock. It's not for the faint of heart. But for those investors comfortable with those risks and owning one of the market's top growth and hotly contested battleground stocks, there are ways to reduce the chances of owning a fatty investment that's unkind to the portfolio.One way to enter into Beyond Meat stock is momentum-based and wait for a price move through $138. This entry is a couple percentage points above the recent high. It makes an allowance for price volatility while also clearing the Fibonacci 38% resistance level. I'd use this week's closing high of $129.18 as an initial stop to guard against possible larger losses.Bottom line, this is a potentially very fast, money-style trade and taking initial profits near the 50% retracement level at $155 makes sense in relation to the risks taken on the price chart. Moreover, with earnings less than two weeks out, this exposure needs to be actively reassessed. And if you're like me, that should include using Beyond Meat stock's options market for more secure, risk-adjusted opportunities.Disclosure: Investment accounts under Christopher Tyler's management currently own positions in Beyond Meat (BYND) stock and its derivatives, but no other securities mentioned in this article. The information offered is based upon Christopher Tyler's observations and strictly intended for educational purposes only; the use of which is the responsibility of the individual. For additional market insights and related musings, follow Chris on Twitter @Options_CAT and StockTwits. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * The 7 Stocks That Cautious Investors Should Sell Now * 7 Healthcare Stocks With 100% Street Support * 3 Chinese Stocks to Buy, Sell, or Play from Either Side The post Is it Time to Come Back for Seconds on Beyond Meat Stock? appeared first on InvestorPlace.
If you love investing in stocks you're bound to buy some losers. But the long term shareholders of Carrols Restaurant...
Carrols operates Restaurant Brands International Inc (NYSE: QSR)-branded restaurants, including 1,035 Burger King restaurants and 65 Popeyes. The company said in a Monday press release that comparable restaurant sales for its Popeyes restaurants rose 21.2% in the fourth quarter. Comparable restaurant sales at Popeyes locations for the full year rose 11.9% from 2018, according to Carrols.